Eli Lilly 2012 Annual Report Download - page 16

Download and view the complete annual report

Please find page 16 of the 2012 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 164

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164

4
• Forteo®, for the treatment of osteoporosis in postmenopausal women and men at high risk for
fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women
• Evista®, for the prevention and treatment of osteoporosis in postmenopausal women and for the
reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis and
postmenopausal women at high risk for invasive breast cancer
• Humatrope®, for the treatment of human growth hormone deficiency and certain pediatric growth
conditions
• Axiron®, a topical solution of testosterone, applied by underarm applicator, for replacement therapy in
men for certain conditions associated with a deficiency or absence of testosterone.
Oncology products, including:
• Alimta®, for the first-line treatment, in combination with another agent, of advanced non-small cell
lung cancer for patients with non-squamous cell histology; for the second-line treatment of advanced
non-squamous non-small cell lung cancer; as monotherapy for the maintenance treatment of
advanced non-squamous non-small cell lung cancer in patients whose disease has not progressed
immediately following chemotherapy treatment; and in combination with another agent, for the
treatment of malignant pleural mesothelioma
• Gemzar®, for the treatment of pancreatic cancer; in combination with other agents, for the treatment
of metastatic breast cancer, non-small cell lung cancer, and advanced or recurrent ovarian cancer;
and in the EU for the treatment of bladder cancer
• Erbitux®, indicated both as a single agent and with another chemotherapy agent for the treatment of
certain types of colorectal cancers; and as a single agent or in combination with radiation therapy for
the treatment of certain types of head and neck cancers.
Cardiovascular products, including:
• Cialis®, for the treatment of erectile dysfunction and benign prostatic hyperplasia
• Effient®, for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients
with acute coronary syndrome who are managed with an artery-opening procedure known as
percutaneous coronary intervention (PCI), including patients undergoing angioplasty, atherectomy, or
stent placement
• ReoPro®, for use as an adjunct to PCI for the prevention of cardiac ischemic complications
• Adcirca®, for the treatment of pulmonary arterial hypertension
• Livalo®, for use as an adjunct to diet in the treatment of high cholesterol (primary hyperlipidemia or
mixed dyslipidemia).
Other pharmaceuticals, including:
• Vancocin® HCl, used primarily to treat staphylococcal infections
• Ceclor™, for the treatment of a wide range of bacterial infections.
Animal Health Products
Our products for food animals include:
• Rumensin®, a cattle feed additive that improves feed efficiency and growth and also controls and
prevents coccidiosis
• Tylan®, an antibiotic used to control certain diseases in cattle, swine, and poultry
• Micotil®, Pulmotil®, and Pulmotil AC, antibiotics used to treat respiratory disease in cattle, swine, and
poultry, respectively
• Paylean® and Optaflexx™, leanness and performance enhancers for swine and cattle, respectively
• Posilac®, a protein supplement to improve milk productivity in dairy cows